IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GUIDETTI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.437
AS - Asia 4.457
NA - Nord America 4.175
SA - Sud America 437
AF - Africa 89
OC - Oceania 78
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.675
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.005
CN - Cina 1.627
DE - Germania 1.221
SG - Singapore 1.136
IT - Italia 1.102
GB - Regno Unito 1.011
RU - Federazione Russa 337
SE - Svezia 337
HK - Hong Kong 315
BR - Brasile 313
FR - Francia 274
VN - Vietnam 272
JP - Giappone 250
IN - India 224
ES - Italia 215
FI - Finlandia 176
NL - Olanda 122
IE - Irlanda 119
BD - Bangladesh 117
TR - Turchia 113
CH - Svizzera 102
UA - Ucraina 100
CA - Canada 97
KR - Corea 82
AU - Australia 74
ID - Indonesia 68
AT - Austria 52
TH - Thailandia 48
MX - Messico 47
BE - Belgio 44
GR - Grecia 43
PL - Polonia 40
AR - Argentina 39
DK - Danimarca 36
CO - Colombia 28
CI - Costa d'Avorio 27
TW - Taiwan 23
CZ - Repubblica Ceca 22
PE - Perù 21
EU - Europa 20
SA - Arabia Saudita 19
IR - Iran 18
PT - Portogallo 17
LB - Libano 16
IQ - Iraq 15
PH - Filippine 15
MA - Marocco 12
UZ - Uzbekistan 12
ZA - Sudafrica 12
IL - Israele 11
JO - Giordania 11
MY - Malesia 11
PK - Pakistan 10
AZ - Azerbaigian 9
EC - Ecuador 9
EG - Egitto 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
BA - Bosnia-Erzegovina 7
CL - Cile 6
CR - Costa Rica 6
HR - Croazia 6
LU - Lussemburgo 6
SC - Seychelles 6
TN - Tunisia 6
GT - Guatemala 5
HU - Ungheria 5
LV - Lettonia 5
NO - Norvegia 5
NP - Nepal 5
PS - Palestinian Territory 5
PY - Paraguay 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
BG - Bulgaria 4
DZ - Algeria 4
EE - Estonia 4
KE - Kenya 4
KZ - Kazakistan 4
LT - Lituania 4
NZ - Nuova Zelanda 4
AL - Albania 3
JM - Giamaica 3
QA - Qatar 3
RO - Romania 3
AM - Armenia 2
BH - Bahrain 2
BO - Bolivia 2
ET - Etiopia 2
GA - Gabon 2
GH - Ghana 2
KW - Kuwait 2
MK - Macedonia 2
NI - Nicaragua 2
PA - Panama 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AD - Andorra 1
BF - Burkina Faso 1
Totale 14.678
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 823
Southend 799
Singapore 662
Ashburn 459
Milan 365
Chandler 280
Hong Kong 273
Beijing 270
San Jose 230
Dallas 148
Seattle 140
Wilmington 135
Helsinki 127
Council Bluffs 124
Fairfield 124
Dublin 118
Los Angeles 99
Princeton 99
New York 97
Hefei 95
Hangzhou 90
Shanghai 83
Ann Arbor 77
Moscow 76
Nanjing 76
Bengaluru 75
Tokyo 75
Dearborn 74
Houston 74
Santa Clara 74
Ho Chi Minh City 72
Guangzhou 69
Jacksonville 67
Woodbridge 63
Hanoi 62
Barcelona 59
Lauterbourg 58
Chicago 53
Columbus 51
Rome 51
Jakarta 50
Munich 46
Buffalo 44
Redwood City 44
Redmond 43
Tianjin 42
São Paulo 41
The Dalles 40
Cambridge 39
Des Moines 36
Serra 36
Vienna 36
Madrid 35
Istanbul 34
Hanover 33
Mountain View 31
London 29
Abidjan 27
Berlin 27
Lugano 27
Paris 27
Jinan 26
Somerville 26
Boston 24
Phoenix 24
Shenzhen 24
Bogotá 23
Brisbane 23
Naples 23
Nuremberg 23
Toronto 23
Nanchang 22
Philadelphia 22
Atlanta 21
Boardman 21
Cangzhou 21
Bangkok 20
Brussels 20
Shenyang 20
Zhengzhou 20
Sakarya 19
San Diego 19
Sydney 19
Wuhan 19
Andover 18
Athens 18
Bologna 18
Fremont 17
Haiphong 17
Stockholm 17
Zurich 17
Chengdu 16
Da Nang 16
Fuzhou 16
Montreal 16
Osaka 16
Seoul 16
Southampton 16
Warsaw 16
Washington 16
Totale 8.381
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 2.097
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside 671
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas 609
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 568
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression 402
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 313
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients 305
A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy 286
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 264
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome 248
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 235
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial 232
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 228
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 223
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 219
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 217
Pomalidomide for the treatment of relapsed and refractory multiple myeloma 215
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 211
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 209
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 209
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 208
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey 206
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 206
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 204
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 197
IFN-γ enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 195
SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma 195
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma : long-term outcomes and graft-versus-host disease-free/relapse-free survival 192
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 190
Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA 189
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 188
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation : Life-threating Features Within the Early Post-engraftment Phase 186
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 184
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor : an algorithm for the pre-emptive use of plerixafor 183
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor 176
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy 173
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 170
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 169
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report 168
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? 167
Early Serum TARC Reduction Predicts Prognosis in Advanced-Stage Hodgkin Lymphoma Patients Treated with a PET-Adapted Strategy 167
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics 161
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy : possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. 160
Methodological framework for radiomics applications in Hodgkin’s lymphoma 160
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 157
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP 155
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies 154
Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma 152
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry 148
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 145
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 143
Radioimmunotherapy and secondary leukemia : a case report 138
Timing of high dose methotrexate CNS prophylaxis in DLBCL : a multicenter international analysis of 1,384 patients 129
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 128
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 126
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 119
Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM 116
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 115
Phase II study of sorafenib in patients with relapsed or refractory lymphoma 108
Resistance to proteasome inhibitors in multiple myeloma 107
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 97
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF 91
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey 79
Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients 77
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey 76
Inflammation and lymphoma: Therapeutic implications 61
Efficacy of antibody–drug conjugate brentuximab vedotin in treating Hodgkin’s lymphoma 52
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study 40
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes 39
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis 27
Totale 15.134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021184 0 0 0 0 0 0 0 0 0 0 140 44
2021/20221.154 100 53 52 47 53 68 69 176 145 104 77 210
2022/20231.550 142 146 111 106 158 225 71 124 148 73 149 97
2023/20242.053 84 103 127 135 274 124 221 213 109 169 234 260
2024/20252.705 176 270 188 226 204 156 144 237 154 207 245 498
2025/20264.254 461 295 429 323 396 323 535 254 548 343 347 0
Totale 15.134